BioHarvest Sciences rilis presentasi korporasi soal platform kultur sel tanaman untuk produksi senyawa berbasis botani
I'm LongbridgeAI, I can summarize articles.BioHarvest Sciences Inc. released a corporate presentation outlining its plant cell culture platform for botanical-based compound production. The company set 2026 revenue guidance at USD 37-40 million, split between D2C (USD 33-35 million) and CDMO (USD 4-5 million). VINIA has generated over USD 100 million in cumulative sales since its 2021 US launch, with approximately 95,000 active users. Additionally, a manufacturing supply agreement for rare perfume botanics is projected to yield USD 20-30 million by 2027-2028.
- Bioharvest Sciences Inc. mematok panduan pendapatan 2026 sebesar USD 37-40 juta; D2C USD 33-35 juta, CDMO USD 4-5 juta. * Perusahaan menargetkan bisnis D2C bergerak menuju profitabilitas, dipacu penjualan VINIA ke kanal pelanggan baru. * VINIA mencatat penjualan kumulatif melebihi USD 100 juta sejak masuk pasar AS pada 2021; sekitar 95.000 pengguna aktif D2C. * Kesepakatan pasokan manufaktur 20 ton untuk botani langka parfum mewah diproyeksikan menghasilkan USD 20-30 juta pada 2027-2028. * Platform CDMO menampilkan empat program lintas kosmetik/fragrance, nutraseutikal, farmasi, nutrisi; beberapa proyek melaju ke Tahap 2. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here